



PATENT.
ATTY. DOCKET NO.: VOSS1130

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Peltonen *et al.*
Application No.: 09/509,595
Filed: July 5, 2000
Title: NUCLEIC ACID MOLECULE ENCODING A (POLY)PEPTIDE
CO-SEGREGATING IN MUTATED FORM WITH AUTOIMMUNE
POLYENDOCRINOPATHY CANDIDIASIS ECTODERMAL
DYSTROPHY (APECED)

Art Unit: 1653
Examiner: K. Carlson

Box Sequence

U.S. Patent and Trademark Office
P.O. Box 2327
Arlington, VA 22202

**STATEMENT UNDER 37 C.F.R. §§ 1.821(f) and (g);
37 C.F.R. §§ 1.825(a) and (b)**

RECEIVED
APR 24 2002
TECH CENTER 1600/2900

Sir:

I hereby state, as required by 37 C.F.R. §§ 1.821(f) and (g), that the information recorded in computer readable form is identical to the written sequence listing and does not include new matter.

I hereby state that the submission, filed in accordance with 37 C.F.R. § 1.825(a), is supported in the application, as shown in the enclosed Amendment, and does not include new matter.

CERTIFICATION UNDER 37 CFR §1.8	
I hereby certify that the documents referred to as enclosed herein are being deposited with the United States Postal Service as first class mail on this date, <u>April 12, 2002</u> , in an envelope addressed to: U.S. Patent and Trademark Office Box Sequence, P.O. Box 2327. Arlington, VA 22202.	
Mikhail Bayley	
Name of Person Mailing Paper	April 12, 2002
Signature	Date

In re Application of:
Peltonen *et al.*
Application No.: 09/509,595
Filed: July 5, 2000
Page 2

PATENT
ATTY. DOCKET NO.: VOSS1130

I hereby state that the substitute copy of the computer readable form, submitted in accordance with 37 C.F.R. § 1.825 (b), is the same as the amended Sequence Listing.

Respectfully submitted,


Date: April 12, 2002



Emanuel J. Vacchiano, Ph.D.
Reg. No. 43,964
Telephone: (858) 638-6754
Facsimile: (858) 677-1465

GRAY CARY WARE & FREIDENRICH LLP
4365 Executive Drive, Suite 1100
San Diego, CA 92121-2133

Customer Number: 28213



Application No.: 09/ 509595

**NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING
NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES**

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):

- ☒ 1. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to these regulations, published at 1114 OG 29, May 15, 1990 and at 55 FR 18230, May 1, 1990.
- ☐ 2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).
- ☐ 3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).
- ☐ 4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing."
- ☐ 5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).
- ☐ 6. The paper copy of the "Sequence Listing" is not the same as the computer readable form of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).
- ☐ 7. Other: the specification and the claims do not have sequence identification numbers at each sequence as required by 37 CFR 1,821(d).

Applicant Must Provide:

- ☒ An initial or substitute computer readable form (CRF) copy of the "Sequence Listing".
- ☒ An initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification.
- ☒ A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).

For questions regarding compliance to these requirements, please contact:

For Rules Interpretation, call (703) 308-4216

For CRF Submission Help, call (703) 308-4212

For PatentIn software help, call (703) 308-6856

PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR RESPONSE

RECEIVED
APR 24 2002
TECH CENTER 1600/2900



PATENT
ATTY. DOCKET NO.: VOSS1130

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Peltonen *et al.* Art Unit: 1653
Application No.: 09/509,595 Examiner: K. Carlson
Filed: July 5, 2000
Title: NUCLEIC ACID MOLECULE ENCODING A (POLY)PEPTIDE
CO-SEGREGATING IN MUTATED FORM WITH AUTOIMMUNE
POLYENDOCRINOPATHY CANDIDIASIS ECTODERMAL
DYSTROPHY (APECED)

Box Sequence

U.S. Patent and Trademark Office
P.O. Box 2327
Arlington, VA 22202

RECEIVED
APR 24 2002
TECH CENTER 1600/2900

VERIFIED STATEMENT UNDER 37 C.F.R. § 1.821(f)

Sir:

I, Mikhail Bayley, declare that I personally prepared the paper and the computer-readable copies of the Sequence Listing filed herewith in the above-entitled case and that the content of both is the same.

I further declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of The United States Code, and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Date: 04/12/2002

Mikhail Bayley
Mikhail Bayley

GRAY CARY WARE & FREIDENRICH LLP
4365 Executive Drive, Suite 1100
San Diego, CA 92121-2133

Customer Number: 28213

CERTIFICATION UNDER 37 CFR §1.8	
I hereby certify that the documents referred to as enclosed herein are being deposited with the United States Postal Service as first class mail on this date, <u>April 12, 2002</u> , in an envelope addressed to: U.S. Patent and Trademark Office Box Sequence, P.O. Box 2327, Arlington, VA 22202.	
Mikhail Bayley	
Name of Person Mailing Paper	April 12, 2002
Signature	Date